Join Growin Stock Community!

Imunon, inc.IMNN.US Overview

US StockHealthcare
(No presentation for IMNN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IMNN AI Insights

IMNN Overall Performance

IMNN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IMNN Recent Performance

-1.54%

Imunon, inc.

0.05%

Avg of Sector

-0.31%

S&P500

IMNN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IMNN Key Information

IMNN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IMNN Profile

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

Price of IMNN

IMNN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IMNN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.68
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
17.94
PB Ratio
2.67
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.68
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
17.94
PB Ratio
2.67
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is IMNN's latest earnings report released?

    The most recent financial report for Imunon, inc. (IMNN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IMNN's short-term business performance and financial health. For the latest updates on IMNN's earnings releases, visit this page regularly.

  • How much debt does IMNN have?

    As of the end of the reporting period, Imunon, inc. (IMNN) had total debt of 1.1M, with a debt ratio of 0.12. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does IMNN have?

    At the end of the period, Imunon, inc. (IMNN) held Total Cash and Cash Equivalents of 5.25M, accounting for 0.58 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is IMNN's EPS continuing to grow?

    According to the past four quarterly reports, Imunon, inc. (IMNN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.16. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IMNN?

    Imunon, inc. (IMNN)'s Free Cash Flow (FCF) for the period is -4.44M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 9.43% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of IMNN?

    The latest valuation data shows Imunon, inc. (IMNN) has a Price-To-Earnings (PE) ratio of -0.89 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.